Literature DB >> 1864973

Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree.

P de Knijff1, A M van den Maagdenberg, A F Stalenhoef, J A Leuven, P N Demacker, L P Kuyt, R R Frants, L M Havekes.   

Abstract

By the careful screening of familial dysbetalipoproteinemic (FD) patients, five probands showing heterozygosity for the APOE*3-Leiden allele were found. Genealogical studies revealed that these probands share common ancestry in the 17th century. In a group of 128 family members, spanning three generations, 37 additional heterozygous APOE*3-Leiden gene carriers were detected. Although with a variable degree of severity, all carriers exhibited characteristics of FD such as (a) elevated levels of cholesterol in the very low density lipoprotein (VLDL) and intermediate density lipoprotein (IDL) fractions, (b) elevated ratios of cholesterol levels in these density fractions over total plasma levels of triglycerides, and (c) strongly increased plasma levels of apolipoprotein E (apoE). Multiple linear regression analysis revealed that most of the variability in expression of FD in APOE*3-Leiden allele carriers can be explained by age. Body mass index showed a less significant influence on the expression of FD. Gender had no effect on the expression in E*3-Leiden allele carriers, nor did it influence the age of onset of FD. In the group of APOE*3-Leiden allele carriers, we found that the E*2 allele enhances the expression of FD, whereas the E*4 allele had the opposite effect. Isoelectric focusing of plasma and of isolated VLDL, IDL, and high density lipoprotein density fractions showed that in E*3-Leiden allele carriers the apoE3-Leiden variant largely predominates over its normal apoE counterpart, especially in the VLDL and IDL density fractions. We conclude that in APOE*3-Leiden allele carriers FD is dominantly inherited with a high rate of penetrance, i.e., the presence of normally functioning apoE molecules in the plasma does not prevent the age-related expression of this disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1864973      PMCID: PMC295406          DOI: 10.1172/JCI115349

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

Review 1.  Type III hyperlipoproteinemia: a focus on lipoprotein receptor-apolipoprotein E2 interactions.

Authors:  T L Innerarity; D Y Hui; T P Bersot; R W Mahley
Journal:  Adv Exp Med Biol       Date:  1986       Impact factor: 2.622

2.  Remnants of lipoproteins of intestinal and hepatic origin in familial dysbetalipoproteinemia.

Authors:  J P Kane; G C Chen; R L Hamilton; D A Hardman; M J Malloy; R J Havel
Journal:  Arteriosclerosis       Date:  1983 Jan-Feb

3.  Apolipoprotein E2-Christchurch (136 Arg----Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia.

Authors:  M R Wardell; S O Brennan; E D Janus; R Fraser; R W Carrell
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

4.  Nucleotide sequence and structure of the human apolipoprotein E gene.

Authors:  Y K Paik; D J Chang; C A Reardon; G E Davies; R W Mahley; J M Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

5.  Apolipoprotein E*3-Leiden allele results from a partial gene duplication in exon 4.

Authors:  A M van den Maagdenberg; P de Knijff; A F Stalenhoef; J A Gevers Leuven; L M Havekes; R R Frants
Journal:  Biochem Biophys Res Commun       Date:  1989-12-15       Impact factor: 3.575

6.  Apolipoprotein E3-Leiden contains a seven-amino acid insertion that is a tandem repeat of residues 121-127.

Authors:  M R Wardell; K H Weisgraber; L M Havekes; S C Rall
Journal:  J Biol Chem       Date:  1989-12-15       Impact factor: 5.157

7.  Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112.

Authors:  K H Weisgraber
Journal:  J Lipid Res       Date:  1990-08       Impact factor: 5.922

Review 8.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology.

Authors:  R W Mahley
Journal:  Science       Date:  1988-04-29       Impact factor: 47.728

9.  A rapid micromethod for apolipoprotein E phenotyping directly in serum.

Authors:  L M Havekes; P de Knijff; U Beisiegel; J Havinga; M Smit; E Klasen
Journal:  J Lipid Res       Date:  1987-04       Impact factor: 5.922

10.  Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions.

Authors:  A Lalazar; K H Weisgraber; S C Rall; H Giladi; T L Innerarity; A Z Levanon; J K Boyles; B Amit; M Gorecki; R W Mahley
Journal:  J Biol Chem       Date:  1988-03-15       Impact factor: 5.157

View more
  19 in total

1.  PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.

Authors:  Brandon Ason; José W A van der Hoorn; Joyce Chan; Edward Lee; Elsbet J Pieterman; Kathy Khanh Nguyen; Mei Di; Susan Shetterly; Jie Tang; Wen-Chen Yeh; Margrit Schwarz; J Wouter Jukema; Rob Scott; Scott M Wasserman; Hans M G Princen; Simon Jackson
Journal:  J Lipid Res       Date:  2014-09-25       Impact factor: 5.922

2.  Very-low-density lipoprotein binding to the apolipoprotein E receptor 2 is enhanced by lipoprotein lipase, and does not require apolipoprotein E.

Authors:  P J Tacken; F D Beer; L C Vark; L M Havekes; M H Hofker
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

Review 3.  Pathogenesis of Lipid Disorders in Insulin Resistance: a Brief Review.

Authors:  Petter Bjornstad; Robert H Eckel
Journal:  Curr Diab Rep       Date:  2018-10-17       Impact factor: 4.810

4.  Characterization of five new mutants in the carboxyl-terminal domain of human apolipoprotein E: no cosegregation with severe hyperlipidemia.

Authors:  A M van den Maagdenberg; W Weng; I H de Bruijn; P de Knijff; H Funke; A H Smelt; J A Gevers Leuven; F M van't Hooft; G Assmann; M H Hofker
Journal:  Am J Hum Genet       Date:  1993-05       Impact factor: 11.025

5.  Ethanol and tobacco smoke increase hepatic steatosis and hypoxia in the hypercholesterolemic apoE(-/-) mouse: implications for a "multihit" hypothesis of fatty liver disease.

Authors:  Shannon M Bailey; Sudheer K Mantena; Telisha Millender-Swain; Yavuz Cakir; Nirag C Jhala; David Chhieng; Kent E Pinkerton; Scott W Ballinger
Journal:  Free Radic Biol Med       Date:  2009-04-01       Impact factor: 7.376

6.  Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice.

Authors:  B J van Vlijmen; A M van den Maagdenberg; M J Gijbels; H van der Boom; H HogenEsch; R R Frants; M H Hofker; L M Havekes
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

7.  Maternal undernutrition programmes atherosclerosis in the ApoE*3-Leiden mouse.

Authors:  Zoe Yates; Elizabeth J Tarling; Simon C Langley-Evans; Andrew M Salter
Journal:  Br J Nutr       Date:  2008-09-10       Impact factor: 3.718

8.  Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146-->Gln) Allele carriers.

Authors:  P de Knijff; A M van den Maagdenberg; D I Boomsma; A F Stalenhoef; A H Smelt; J J Kastelein; A D Marais; R R Frants; L M Havekes
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

Review 9.  Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline.

Authors:  Lars Berglund; John D Brunzell; Anne C Goldberg; Ira J Goldberg; Frank Sacks; Mohammad Hassan Murad; Anton F H Stalenhoef
Journal:  J Clin Endocrinol Metab       Date:  2012-09       Impact factor: 5.958

10.  Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia.

Authors:  M van Dam; M Zwart; F de Beer; A H M Smelt; M H Prins; M D Trip; L M Havekes; P J Lansberg; J J P Kastelein
Journal:  Heart       Date:  2002-09       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.